Annex 1 Compliance Checklist for Australian Sterile Manufacturers

TAKEWAY

This checklist highlights the areas most likely to create gaps during an Annex 1, CCS or TGA readiness review.

Use this checklist before your next Annex 1 readiness review

Australian sterile manufacturers are under increasing pressure to show that contamination risks are understood, controlled and actively managed.

Contamination Control Strategy

Confirm that your CCS connects facility design, process controls, cleaning, disinfection, environmental monitoring, utilities, personnel flows, deviations and CAPA into one coherent control framework. The CCS should be specific enough to support inspection questions, change control and periodic review.

Facility and equipment design

Review whether cleanroom layouts, pressure cascades, material transfers, RABS, isolators, single-use assemblies and fill-finish equipment reduce contamination risk by design rather than relying mainly on procedural controls.

Aseptic process controls

Check that aseptic manipulations are minimized, justified and supported by validated interventions, operator qualification, media fills, transfer controls and clear batch record evidence.

Environmental monitoring and process verification

Verify that monitoring locations, alert/action limits, trend reviews, viable and non-viable data, and investigation triggers are risk-based and linked to actual process contamination hazards.

CAPA roadmap and project delivery

Prioritize gaps by patient risk, regulatory exposure, implementation complexity and project dependency. Convert the gap list into a practical roadmap with owners, timelines, interim controls and verification steps.

Need an independent Annex 1 gap assessment?

NAON supports Australian pharma and biotech teams with Annex 1 gap assessments, CCS reviews, sterility assurance and GMP project delivery.

Book an Annex 1 readiness call to identify the few remediation actions with the highest impact.